Stay updated on Nivolumab Dose Optimization Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Dose Optimization Clinical Trial page.

Latest updates to the Nivolumab Dose Optimization Clinical Trial page
- Check7 days agoChange DetectedAdded related topic sections: Lung cancer and MedlinePlus Genetics to the page for disease context. These changes provide quick access to disease-related information but do not alter the study data or trial details.SummaryDifference0.1%

- Check14 days agoChange DetectedAdded Revision: v3.4.2 to the page. Removed the previous government-funding notices and Revision: v3.4.1.SummaryDifference0.2%

- Check21 days agoChange DetectedAdded a site-wide government funding notice indicating potential delays and that the NIH Clinical Center is open, and updated the site version to Revision: v3.4.1. Removed the 'Lung cancer' topic and related topics (MedlinePlus Genetics) and dropped the older Revision: v3.4.0.SummaryDifference0.3%

- Check28 days agoChange DetectedShow glossary added to the page and a new Study Record Dates field 'Last Update Submitted that Met QC Criteria' (with capitalization adjustments in related labels). The page also includes a revision note 'Revision: v3.4.0' and minor capitalization changes for 'No FEAR Act Data' vs 'No FEAR Act data'.SummaryDifference0.1%

- Check35 days agoChange DetectedThe page now includes additional related topics: Lung cancer and MedlinePlus Genetics; no deletions were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.4 was added; related topics such as Lung cancer and MedlinePlus Genetics were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Dose Optimization Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Dose Optimization Clinical Trial page.